Sign in with Google. Opens in new tab
ENTITY
Biogen Inc

Biogen Inc (BIIB US)

134
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
12 Jul 2022 15:15

Data Mining Technical Publications to Rank the Innovators in RNA Therapeutics

Specialists lead the RNA intellectual property ecosystem but may still need big pharma  to bring new treatments to market making the space ripe for...

Logo
422 Views
Share
bullishEisai Co Ltd
12 Jul 2022 11:41

Eisai Co (4523 JP): Trying Another Luck for Alzheimer’s Disease; Strengthening Presence in Oncology

Eisai is expected to receive FDA approval for its second Alzheimer’s disease drug, lecanemab in Q1 2023. The company is also aiming for submission...

Logo
479 Views
Share
bearishCopper
28 Jun 2022 15:38

Signs of Disinflation?; Commodities Deteriorating; Another Bear Market Bounce; Pharma/Biotech Buys

A bear market bounce is underway after the SPX, QQQ, and IWM found support at their respective downtrend channels. Until these indexes can break...

Logo
435 Views
Share
22 Jun 2022 14:46

Downgrading Materials; SPX, NDX, Russell 2000 Testing Downtrend Channel Support; Biotech Buys

We remain bearish as long as the 6-8 month downtrends remain intact on the SPX, NDX (QQQ), and RUT (IWM). Bounce potential given SPX, QQQ, and IWM...

Logo
486 Views
Share
bullishBiogen Inc
21 May 2022 17:37

Biogen Inc.: Financial & Price Forecasts

Biogen’s failure of its Alzheimer’s drug, Aduhelm has led to a CEO change with the company looking for a successor to CEO Michael Vounatsos. The...

Logo
119 Views
Share
x